BofA Securities analyst Jason Zemanski reiterated an Underperform rating and $1.78 price target on Esperion Therapeutics (NASDAQ: ESPR)The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE